Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7361-7367

  Fox, Elizabeth ^a   Widemann, Brigitte C ^a   Hawkins, Douglas S ^b   Jayaprakash, Nalini ^a   Dagher, Ramzi ^a   Aikin, Alberta A ^a   Bernstein, Donna ^a   Long, Lauren ^a   Mackall, Crystal ^a   Helman, Lee ^a   Steinberg, Seth M ^a   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; RAZOXANE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CD34 SELECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULARY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; THROMBOCYTE TRANSFUSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ANTIGENS, CD34; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FILGRASTIM; HUMANS; NEUTROPENIA; NEUTROPHILS; SARCOMA; TIME FACTORS; YOUNG ADULT;

EID: 73149103973     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0761     Document Type: Article

References (22)

1. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-8.
2. Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 2003;23:9-14S.
3. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004;10:1235-44.
4. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
5. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31.
6. Bhana N. Granulocyte colony-stimulating factors in the management of chemotherapyinduced neutropenia: evidence based review. Curr Opin Oncol 2007;19:328-35.
7. Vogel CL,Wojukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multi-center, double blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84.
8. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB. Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006;46:747-57.
9. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
10. Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: ameta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3350-6.
11. Parsons SK, Mayer DK, Alexander SW, Xu R, Land V, Laver J. Growth factor practice patterns among pediatric oncologists: results of a 1998 Pediatric Oncology Group Survey. Economic Evaluation Working Group the Pediatric Oncology Group. J Pediatr Hematol Oncol 2000;22:227-41.
12. Andre N, Kababri ME, Bertrand P, et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 2007;18:277-81.
13. Koontz SE, Mohassel LR, Jaffe N, et al. Safety and efficacy of pegfilgrastim in pediatric oncology patients: The M.D. Anderson Cancer Center experience. J Clin Oncol 2004;22:8272.
14. Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J Pediatr Hematol Oncol 2005;27:449-51.
15. te Poele EM, Kamps WA, Tamminga RY, Leeuw JA, Postma A, de Bont ES. Pegfilgrastim in pediatric cancer patients. J Pediatr Hematol Oncol 2005;27:627-9.
16. Spunt S, Sender L, Santana VM. Pegfilgrastim in pediatric patients receiving dose-intensive chemotherapy for sarcoma [abstract 3209]. Proc Am Soc Clin Oncol 2003;22.
17. Wexler LH, DeLaney TF, Tsokos M, et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996;78:901-11.
18. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996;14:362-72.
19. Yang BB, Lum PK, Hayashi MM, Roskos LK. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci 2004;93:1367-73.
20. Pinto L, Lui Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfilgrastim with filgrastim on febrile neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-95.
21. Crawford J. Neutrophil growth factors. Curr Hematol Rep 2002;1:95-102.
22. Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006;46:180-5.